Treatment with PCSK9 monoclonal antibodies is associated with discontinuation of oral lipid lowering therapy
In this high-risk cohort of incident PCSK9 mAb users, more than 1 out of 2 stopped taking statin treatment whereas 40% discontinued ezetimibe. There is a major potential for improving adherence to oral LLD treatment following initiation of PCSK9 mAb.
Authors
- Henrik Støvring (ORCID: https://orcid.org/0000-0002-5821-2351)
- Ingrid Engebretsen (ORCID: https://orcid.org/0000-0001-9608-6731)
- Kristina Malene Ødegaard (ORCID: https://orcid.org/0000-0001-8520-0316)
- Ivar Sønbø Kristiansen (ORCID: https://orcid.org/0000-0002-5389-6010)
- Sigrun Halvorsen (ORCID: https://orcid.org/0000-0001-7561-7644)
- Christoffer Bugge (ORCID: https://orcid.org/0000-0002-0766-2870)
- John Munkhaugen (ORCID: https://orcid.org/0000-0001-6141-2162)
Institutions
- Oslo University Hospital (NO)
- Steno Diabetes Centers (DK)
- University of Southern Denmark (DK)
- OsloMet – Oslo Metropolitan University (NO)
- University of Oslo (NO)
- Aarhus University (DK)
- Drammen Hospital (NO)
- 657 Oslo (NO)
- Novartis (Norway) (NO)
Publication Details
- Journal
- European Heart Journal - Quality of Care and Clinical Outcomes
- Published
- 2024-11-18
- DOI
- https://doi.org/10.1093/ehjqcco/qcae099
- Citations
- 6
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 3.44